American Superconductor Corporation vs Baxter International Inc — how do they compare? American Superconductor Corporation trades at $32.38 (market cap $1.56B), while Baxter International Inc trades at $27.11 (market cap $14.27B). The key difference: Baxter International Inc is far larger — about 9.1× American Superconductor Corporation's market cap, and Baxter International Inc pays a 0.14% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| AMSC | BAX | |
|---|---|---|
Market Cap | $1.56B | $14.27B |
Sector | Technology | Health |
52-Week High | $66.68 | $28.35 |
52-Week Low | $25.95 | $15.80 |
Enterprise Value | $1.42B | $21.79B |
Dividend Yield | — | 0.14% |
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.64, up 5.32% in 24 hours, with a bearish technical signal from moving averages. Recent Q1 2026 earnings missed estimates despite record revenue growth, while Q4 2025 and Q1 2026 beat expectations. The company shows strong profitability with a net income margin of 42.56% and ROE of 30.16%, but faces margin pressure and a high EV/EBITDA of 65.73. News highlights record orders and backlog growth amid concerns over valuation and business mix.
Outlook is mixed: bullish fundamentals from earnings beats and order momentum contrast with bearish technicals and valuation risks. Opportunities lie in Grid and Wind segment expansion, but investors face headwinds from margin compression and competitive pressures. Analyst consensus leans buy (53.33%), suggesting cautious optimism for growth execution.
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
Trailing returns across standard periods
Latest headlines on both assets
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →